Target intelligence / Profile preview

Interleukin-2 receptor subunit beta (IL2RB) (IL2RB)

Target
IL2RB
Molecular classification
Receptor, Type I cytokine receptor family, Hematopoietin receptor family
01

Overview

Interleukin-2 receptor subunit beta (IL-2Rβ), also known as CD122, is a type I cytokine receptor that serves as a shared signaling component for both interleukin-2 (IL-2) and interleukin-15 (IL-15) (UniProt P14784). It is primarily expressed on natural killer (NK) cells and effector T cells, where it associates with the common gamma chain (CD132) to form a medium-affinity receptor complex capable of initiating the JAK/STAT signaling pathway, specifically activating JAK1, JAK3, and STAT5 (NCBI Gene 3560). In the field of adoptive cell therapy, IL-2Rβ is a focal point for engineering NK cells to enhance their persistence and anti-tumor potency; this is often achieved by co-expressing membrane-bound cytokines like mbIL-15 or synthetic receptors that provide constitutive survival signals. Therapeutically, targeting IL-2Rβ with biased agonists like Bempegaldesleukin or IL-15 superagonists like N-803 aims to selectively expand cytotoxic immune cells while avoiding the activation of regulatory T cells (Tregs), which require the IL-2 receptor alpha chain (CD25) for high-affinity binding. This strategy is being extensively explored in oncology to treat various solid and hematological malignancies by overcoming the immunosuppressive tumor microenvironment. Additionally, IL-2Rβ signaling is critical for the maturation and functional readiness of NK cells, making it a primary target for ex vivo expansion protocols.

Other names
CD122IL-2R subunit betaIL-2RBP70-75Interleukin-15 receptor subunit betaIL2RB
02

Mechanism of action

Agonism of the IL-2/IL-15 receptor beta/gamma complex to induce proliferation and activation of NK cells and CD8+ T cells.

03

Biological functions

Signal transductionImmune responseCell proliferationCell survivalJAK-STAT signaling pathway
04

Disease associations

CancerAutoimmune diseaseInfection
05

Safety considerations

Capillary leak syndromeCytokine release syndromeImmune-related adverse eventsOff-target Treg activation
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

CD122 expressionSTAT5 phosphorylationNK cell expansionSoluble CD122 levels

Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Interleukin-2 receptor subunit beta (IL2RB) (IL2RB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-2 receptor subunit beta (IL2RB) (IL2RB).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call